Journal of investigative and clinical dentistry · 2017
Clinical and microbiological efficacy of 4% Garcinia mangostana L. pericarp gel as local drug delivery in the treatment of chronic periodontitis: A randomized, controlled clinical trial.
СтатьяРандомизированное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mahendra Jaideep, Mahendra Little, Svedha Priyadharshini, Cherukuri Sandhya, Romanos Georgios E
Аннотация
AIM: The aim of the present study was to assess the periodontal status of individuals and the presence of red complex microorganisms (RCM), such as Treponema denticola (Td), Porphyromonas gingivalis, and Tannerella forsythia in the subgingival tissues of periodontitis patients before and after the application of 4% mangostana gel (Garcinia mangostana [MGA]) as an adjunct to scaling and root planing (SRP).
METHODS: Twenty-five patients (MGA group) were treated with SRP, and the subgingival application of mangostana gel was used as local drug delivery. Twenty-five patients (placebo group) were treated with SRP and placebo gel. Clinical parameters were recorded, and the presence of RCM was assessed at baseline and at the third month.
RESULTS: Clinical parameters, such as probing pocket depth, clinical attachment level, bleeding index, plaque index, and Td, were significantly reduced in the MGA group compared to the placebo group from baseline to the third month.
CONCLUSION: There was a significant improvement in the periodontal status with a reduction in Td with the application of mangostana gel in periodontal pockets. In the near future, 4% mangostana gel can be used as an adjunct to SRP to provide a new dimension to periodontal therapy.
METHODS: Twenty-five patients (MGA group) were treated with SRP, and the subgingival application of mangostana gel was used as local drug delivery. Twenty-five patients (placebo group) were treated with SRP and placebo gel. Clinical parameters were recorded, and the presence of RCM was assessed at baseline and at the third month.
RESULTS: Clinical parameters, such as probing pocket depth, clinical attachment level, bleeding index, plaque index, and Td, were significantly reduced in the MGA group compared to the placebo group from baseline to the third month.
CONCLUSION: There was a significant improvement in the periodontal status with a reduction in Td with the application of mangostana gel in periodontal pockets. In the near future, 4% mangostana gel can be used as an adjunct to SRP to provide a new dimension to periodontal therapy.